NVIDIA and Eli Lilly announce a $1 billion joint investment over five years in AI co-innovation lab for drug discovery at J.P. Morgan Healthcare Conference. Lab will combine Lilly’s expertise with NVIDIA’s AI infrastructure and Vera Rubin architecture to accelerate medicine development and production through robotics and physical AI.

The AI co-innovation lab in San Francisco will bring together Lilly’s experts in biology with NVIDIA’s AI model builders to advance drug discovery. Initial focus is on creating a continuous learning system to connect wet labs with dry labs for 24/7 AI-assisted experimentation. The lab will harness NVIDIA BioNeMo platform and Vera Rubin architecture for next-generation foundation and frontier models in biology and chemistry.

Beyond drug discovery, NVIDIA and Lilly will explore AI applications across clinical development, manufacturing, and commercial operations. Physical AI and robotics will enhance Lilly’s manufacturing capacity and supply chain reliability. Using Omniverse libraries and RTX PRO Servers, Lilly can create digital twins to optimize supply chains before making physical changes.

NVIDIA’s open-source AI and Inception program empower companies with resources for real-world AI systems. Lilly TuneLab provides biotech companies access to Lilly’s proprietary data models for drug discovery, including NVIDIA Clara open foundation models for life sciences. The co-innovation lab will support NVIDIA and Lilly’s startup ecosystems with expertise and computing resources.

Read more at Nvidia: NVIDIA and Lilly Announce Co-Innovation AI Lab to Reinvent Drug Discovery in the Age of AI